StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
WHWKWhitehawk Therapeutics, Inc.
stockpulse.co.kr
Nasdaq
$3.20▼ 0.16%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $172.1MShares out 53.8M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

16
  • 9.18After-hours26.09.19 05:45
    4/AOwnership#●●●

    Whitehawk Therapeutics, Inc.

    Whitehawk Therapeutics insider Scott M. Giacobello has filed a Form 4/A to amend the report regarding changes in beneficial ownership of securities as of September 15, 2026. This filing serves to correct the previously reported insider shareholding information.…more

    $3.20-0.16%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 9.18After-hours26.09.19 05:44
    4/AOwnership

    Whitehawk Therapeutics, Inc.

    Insider Bryan Ball of Whitehawk Therapeutics has filed a Form 4/A to amend the report regarding beneficial ownership of securities as of September 15, 2026. This filing serves to correct previously reported insider transaction details and does not involve changes to the company's capital structure or financial position.…more

    $3.20-0.16%vs prev close
    View filingShare
  • 9.18After-hours26.09.19 05:43
    4/AOwnership

    Whitehawk Therapeutics, Inc.

    Insider David Dornan of Whitehawk Therapeutics, Inc. has filed a Form 4/A to amend the statement of changes in beneficial ownership of securities as of September 15, 2026. This filing serves as a correction to the reporting of the insider's equity holdings.…more

    $3.20-0.16%vs prev close
    View filingShare

15 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 10.1Pre-market26.10.01 21:05
    #●●●#●●●#●●●

    Whitehawk Therapeutics Presents MUC16 Target Data for HWK-016

    Whitehawk Therapeutics released real-world analysis data supporting the potential of its MUC16-directed ADC, HWK-016. The findings confirm stable MUC16 expression after standard therapies, reinforcing the rationale for its ongoing Phase 1 development.…more

    $3.20-0.16%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    ShareBenzinga
  • 9.14Overnight26.09.14 14:36

    ●●●●●●●● ●●●●● ●●●●●●

    Whitehawk reported that PTK7 expression remains stable after standard-of-care therapies, supporting the clinical relevance of its ADC candidate HWK-007. The drug is currently undergoing Phase 1 development for EGFR wild-type non-small cell lung cancer.…more

    $3.20-0.16%vs prev close
    ShareBenzinga

1 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →